Table 1.
Characteristics of the survivor population
| N | % | |
|---|---|---|
| Sex | ||
| Female | 303 | 49·7 |
| Male | 307 | 50·3 |
| Race/ethnicity | ||
| White | 543 | 89·0 |
| Black | 22 | 3·6 |
| Hispanic | 24 | 3·9 |
| Other/unknown | 21 | 3·4 |
| Diagnosis | ||
| Soft tissue sarcoma | 145 | 23·8 |
| Ewing sarcoma | 103 | 16·9 |
| Osteosarcoma | 346 | 56·7 |
| Other bone tumors | 16 | 2·6 |
| Lower extremity surgery | ||
| Hemipelvectomy | 15 | 2·5 |
| Transfemoral amputation | 264 | 43·3 |
| Transtibial amputation | 36 | 5·9 |
| Limb sparing surgery | 214 | 35·1 |
| No bone surgery | 81 | 13·3 |
| Lung surgery (excluding biopsy) | ||
| No | 519 | 85·1 |
| Yes | 91 | 14·9 |
| Chest or lung radiation | ||
| No | 574 | 94·1 |
| Yes | 36 | 5·9 |
| Local radiation | ||
| No | 455 | 74·6 |
| Yes | 155 | 25·4 |
| Vinca alkaloid | ||
| No | 257 | 42·1 |
| Yes | 353 | 57·9 |
| Anthracycline | ||
| No | 174 | 28·5 |
| Yes | 436 | 71·5 |
| Bleomycin | ||
| No | 474 | 77·7 |
| Yes | 136 | 22·3 |
| Platinum | ||
| No | 477 | 78·2 |
| Yes | 133 | 21·8 |
| Annual household income at follow-up | ||
| <$40,000 | 145 | 23·8 |
| $40,000+ | 439 | 72·0 |
| Not indicated | 26 | 4·3 |
| Persistent cancer related pain at follow-up | ||
| None or mild | 452 | 74·1 |
| Moderate or greater | 156 | 25·6 |
| Not indicated | 2 | 0·3 |
| Anxiety as a result of cancer at follow-up | ||
| None or mild | 521 | 85·4 |
| Moderate or greater | 86 | 14·1 |
| Not indicated | 3 | 0·5 |
| Depression at baseline | ||
| T-score < 63 on Brief Symptom Inventory | 558 | 91·5 |
| T-score 63+ on Brief Symptom Inventory | 46 | 7·5 |
| Not indicated | 6 | 1·0 |
| Current smoker at follow-up | ||
| Yes | 100 | 16·4 |
| No | 508 | 83·3 |
| Not indicated | 2 | 0·3 |
| Body mass index at follow-up | ||
| < 30 kilograms per meter squared | 457 | 74·9 |
| 30+ kilograms per meter squared | 135 | 22·1 |
| Not indicated | 18 | 3·0 |